ARYNTA

Launch

lisdexamfetamine dimesylate

NDAORALSOLUTION
Approved
Jun 2025
Lifecycle
Launch
Competitive Pressure
0/100
Clinical Trials
9

Mechanism of Action

dextroamphetamine. Amphetamines are non-catecholamine sympathomimetic amines with CNS stimulant activity. The exact mode of therapeutic action in ADHD and BED is not known.

Clinical Trials (5)

NCT06847399Phase 2Recruiting

Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder

Started Sep 2025
105 enrolled
Obesity and OverweightBinge Eating Disorder
NCT01328756Phase 4Completed

Lisdexamfetamine Dimesylate 2-year Safety Study in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)

Started Jul 2011
314 enrolled
Attention Deficit Hyperactivity Disorder (ADHD)
NCT01106430Phase 3Completed

Comparison of Lisdexamfetamine Dimesylate With Atomoxetine HCl in Attention-Deficit/Hyperactivity Disorder (ADHD) Subjects With an Inadequate Response to Methylphenidate

Started Jun 2010
267 enrolled
Attention-Deficit/Hyperactivity Disorder
NCT01010750Phase 1Completed

Lisdexamfetamine Dimesylate (LDX) Pilot Cognition Study to Evaluate the Utility of a Standardized Battery of Tests in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

Started Jan 2010
18 enrolled
Attention-Deficit Hyperactivity Disorder
NCT00763971Phase 3Completed

Randomized, Double-blind Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17

Started Nov 2008
336 enrolled
ADHD

Loss of Exclusivity

LOE Date
Aug 30, 2040
176 months away
Patent Expiry
Aug 30, 2040

Patent Records (2)

Patent #ExpiryTypeUse Code
12433859
Apr 16, 2040
Product
U-842
11576878
Aug 30, 2040
Product